The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SITC 2021 | COVID-19 vaccination in patients with RCC and melanoma treated with immune checkpoint inhibitors
Hannah E. Dzimitrowicz, MD, Duke Cancer Center, Durham, NC, discusses a study investigating the effect of COVID-19 vaccination in patients with renal cell carcinoma (RCC) or melanoma receiving immune checkpoint inhibitor (ICI) therapy. The patients in the study were on ICI therapy when they received their COVID-19 vaccination and were compared to a control group who were not on immunotherapy. The aim of the study was to investigate the effect of the vaccine on these patients in terms of efficacy and safety. The overall conclusion was that the vaccine was safe for these patients. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.
